Brent Pfeiffenberger
Brent Pfeiffenberger's purchase track record
Brent Pfeiffenberger has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/12/2025 | IPSC | $30K | +319.3% | +303.2% | +8.8% |
| 11/19/2025 | IPSC | $17K | +306.2% | +335.2% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Butterfly Network Announces Long‑Term Alliance with VCOM and Gains New Coverage. Butterfly Network entered a long‑term partnership with the Edward Via College of Osteopathic Medicine to develop a new ultrasound education model. The collaboration aims to expand training tools for medical students. In addition, Canaccord Genuity started coverage on the stock, setting a price target of $10. The move reflects growing interest in Butterfly’s technology and its educational applications.
Transaction History
| IPSC | ▼ Sell | Tax Withholding | 13,850 | $27K | 9/11/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 463 | $977 | 9/4/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 31,172 | $60K | 8/14/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 13,849 | $31K | 6/11/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 463 | $986 | 6/5/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 7,500 | $0 | 5/19/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 31,172 | $73K | 5/15/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 55,397 | $151K | 3/11/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 463 | $1K | 3/6/2026 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 31,172 | $55K | 2/13/2026 | View on chart |
| IPSC | ▲ Buy | Grant | 475,000 | $0 | 2/2/2026 | View on chart |
| IPSC | ▲ Buy | Open Market | 52,000 | $30K | 12/12/2025 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 463 | $244 | 12/10/2025 | View on chart |
| IPSC | ▲ Buy | Open Market | 35,000 | $17K | 11/19/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 32,456 | $15K | 11/17/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 488 | $244 | 9/8/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 1,587,614 | $0 | 8/14/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 475 | $295 | 6/9/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 29,552 | $16K | 5/16/2025 | View on chart |
| IPSC | ▲ Buy | Grant | 521,500 | $0 | 3/11/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 2,235 | $1K | 3/10/2025 | View on chart |
| IPSC | ▼ Sell | Open Market | 34,712 | $27K | 2/18/2025 | View on chart |
| IPSC | ▼ Sell | Tax Withholding | 243,447 | $351K | 12/4/2024 | View on chart |
| IPSC | ▲ Buy | Grant | 17,425 | $0 | 3/7/2024 | View on chart |
| BFLY | ▲ Buy | Grant | 17,425 | $0 | 3/7/2024 | View on chart |
| IPSC | ▲ Buy | Grant | 279,504 | $0 | 12/4/2023 | View on chart |
| IPSC | ▲ Buy | Grant | 1,173,775 | $0 | 12/4/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Century Therapeutics faces competitive pressure on key strategy
A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.
Century Therapeutics faces competitive pressure on key strategy. A recent analysis suggests that competitors are taking steps to reduce the risks associated with Century Therapeutics' primary business focus. This development is relevant as it may impact the company's market position and future prospects. The stock is currently trading near its support levels, reflecting ongoing uncertainty in the market.